Current Clinical Trials
Listed below are a few of our enrolling studies. If you do not see a condition that you are interested in please check back or contact us. We may have opportunities that are in the development phase or may consider your inquiry for future studies.
Gilead RAINIER IPF Clinical Trial
If you know someone diagnosed with idiopathic pulmonary fibrosis (IPF), they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital. The research is testing an investigational drug, Simtuzumab, compared to placebo (a safe, inactive substance) for benefits and safety. To qualify one must be 45-85 years of age, diagnosed within the last 3 years and not listed as active on a lung transplant waiting list. Compensation for study related travel expenses may be provided. For more information please contact a study coordinator at 414-955-7030 or firstname.lastname@example.org
KaloBios KB001A-05 for Cystic Fibrosis
If you or someone you know has cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection, they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital. The research is designed to determine if multiple doses of KB001-A are safe and effective in people with CF and chronic Pa infection. Key criteria to qualify for this study include: ages 18 to 50 years, diagnosis of cystic fibrosis, respiratory tract culture with P. aeruginosa present in >50% of cultures within past 12 months, and a FEV1 between ≥40% and ≤80% predicted at screening. For more information please call Study Coordinator, Diana Rosik at 414-955-7085 or e-mail: email@example.com
Insmed / Arikace 112 NTM PRO 17798
If you or someone you know has been diagnosed with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) and/or Mycobacterium abscessus, they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital.
The research is designed to assess the safety and effectiveness of an inhaled investigational drug, Arikace, compared to placebo (an inactive substance). Key criteria to qualify for this study include: age 18 - 85 years old, diagnosis of NTM lung disease, positive sputum culture with MAC and/or M. Abscessus at screening, and receiving multi-drug treatment regimen for at least 6 months prior to screening. For more information please call Study Coordinator, Rachel Harris at 414-955-7030 or e-mail: firstname.lastname@example.org
You must also have the ability to come in for frequent visits and be available for weekly phone calls.
For more information please contact a Study Coordinator at 414-955-7030 or email email@example.com